MODERN POSSIBILITIES OF THERAPY WITH INHIBITORS OF CONTROL POINTS IN METASTATIC UROTHELIAL CANCER

For a long time, chemotherapy remained the main treatment option for metastatic urothelial carcinoma (mUC). Over the past year, there have been revolutionary changes associated with the approval of five new drugs aimed at blocking the interaction between the surface protein of T-lymphocytes PD-1 and...

Descrizione completa

Dettagli Bibliografici

Autori principali:	R. A. Gafanov, S. V. Garmash, I. B. Kravtsov, S. V. Fastovets
Natura:	Artigo
Lingua:	Russo
Pubblicazione:	QUASAR, LLC 2018-03-01
Serie:	Исследования и практика в медицине
Soggetti:	bladder cancer pd-1 pd-l1 immunotherapy atezolizumab nivolumab pembrolizumab avelumab durvalumab
Accesso online:	https://www.rpmj.ru/rpmj/article/view/246
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!